Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes
Cancer Science · 2026
DOI: 10.1111/cas.70400 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Science, 2026. Verfasst von Yutaro Nagano und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan. Hauptthemen laut MEDLINE: Acrylamides, Afatinib, Aniline Compounds, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sapporo Medical University Grants for Programs promoting Academic advancements.
Abstract (Originalsprache)
Non–small cell lung cancers (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations (UMs) are clinically heterogeneous, and the optimal first‐line EGFR tyrosine kinase inhibitor (EGFR‐TKI), as well as the role of subsequent immune checkpoint inhibitor (ICI)–based regimens, remains uncertain. We conducted a multicenter retrospective cohort study including patients with advanced or recurrent non‐squamous NSCLC harboring UMs who received first‐line afatinib or osimertinib between January 2015 and January 2024 at 29 hospitals in Japan, excluding exon 20 insertions and de novo T790M mutations. Inverse probability of treatment weighting adjusted baseline imbalances, and post–EGFR‐TKI treatment patterns were evaluated. Among 162 patients (afatinib, n = 95; osimertinib, n = 67), weighted analyses demonstrated no significant differences in time to treatment failure (hazard ratio [HR], 1.04; 95% confidence interval [CI], 0.61–1.77) or overall survival (HR, 1.34; 95% CI, 0.73–2.44). Afatinib was associated with higher response rates and more frequent adverse events requiring dose reduction. Subgroup analyses suggested differential treatment effects according to mutation subtype, with osimertinib favoring L861X mutations and afatinib favoring compound mutations. Among 56 patients who received subsequent systemic therapy, clinical outcomes were comparable between ICI plus platinum doublet and platinum doublet alone. These findings indicate that afatinib and osimertinib provide comparable survival outcomes as first‐line therapies for NSCLC with UMs, with treatment effects varying by molecular subtype, while subsequent ICI‐based regimens may confer limited additional benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan.
- Department of Respiratory Medicine, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.
- Department of Respiratory Medicine, Sapporo Minami-Sanjo Hospital, Sapporo, Japan.
- Department of Respiratory Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan.
- Department of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama, Japan.
ORCID-Profile: Yutaro Nagano, Toshiyuki Sumi, Takaaki Sasaki
Förderung
- Sapporo Medical University Grants for Programs promoting Academic advancements
Zitieren
APA
Nagano, Y., Yokouchi, H., Saito, R., Honjo, O., Sumi, T., Kaburagi, T., Ito, K., Ikezawa, Y., Yokoo, K., Kikuchi, H., Kudo, S., Yamazoe, M., Shigaki, R., Tagami, K., Tenma, T., Ishikawa, T., Takahashi, M., Sasaki, T., Asahina, H., …, & Oizumi, S. (2026). Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes. Cancer Science. https://doi.org/10.1111/cas.70400
Vancouver
Nagano Y, Yokouchi H, Saito R, Honjo O, Sumi T, Kaburagi T, et al. Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes. Cancer Science. 2026. doi:10.1111/cas.70400
BibTeX
@article{Nagano2026,
author = {Nagano, Yutaro and Yokouchi, Hiroshi and Saito, Ryota and Honjo, Osamu and Sumi, Toshiyuki and Kaburagi, Takayuki and Ito, Kenichiro and Ikezawa, Yasuyuki and Yokoo, Keiki and Kikuchi, Hajime and Kudo, Sayaka and Yamazoe, Masami and Shigaki, Ryota and Tagami, Keita and Tenma, Toshiyuki and Ishikawa, Tatsuru and Takahashi, Mamoru and Sasaki, Takaaki and Asahina, Hajime and Hinotsu, Shiro and Chiba, Hirofumi and Oizumi, Satoshi},
title = {Afatinib Versus Osimertinib for Non‐Small Cell Lung Cancer With Uncommon EGFR Mutations: Real‐World Outcomes},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70400}
}
EUVIMED